GSK Reports Results of Jemperli in Combination with Chemotherapy in P-III Trial for the Treatment of Endometrial Cancer
Shots:
- The P-III (RUBY/ENGOT-EN6/GOG3031/NSGO) clinical trial evaluates the safety & efficacy of Jemperli (dostarlimab) + SoC CT (carboplatin & paclitaxel) vs PBO in patients with primary advanced or recurrent endometrial cancer
- The results depicted a clinically meaningful OS in prespecified subpopulations of the trial (dMMR/MSI-H & MMRp/ MSS) whereas previously, the trial depicted a PFS with 72% & 36% reduction in the risk of disease progression or death in dMMR/MSI-H & overall patient population
- Jemperli, a PD-1 blocking Ab that binds to the PD-1 receptor & blocks its interaction with PD-1 ligands, received various regulatory approvals for the treatment of endometrial cancer based on the positive PFS data
Ref: GSK | Image: GSK
Related News:- GSK Receives the EMA’s CHMP Positive Opinion of Jemperli (dostarlimab) for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
